LL-37 vs PNC27
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cathelicidin, CAP18
A naturally occurring antimicrobial peptide and the only human cathelicidin. Part of the innate immune system with broad-spectrum antimicrobial activity.
Also: PNC-27, p53-HDM2 Disruptor Peptide
A chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. Selectively kills cancer cells by binding to HDM-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected.
Key Comparison Insights
- Both peptides belong to the Immune category, suggesting similar primary applications.
- LL-37 has stronger research evidence (Human Trials) compared to PNC27 (Animal Studies).
Detailed Comparison
| Attribute | LL-37 | PNC27 |
|---|---|---|
| Category | Immune | Immune |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | LL-37 directly kills bacteria, fungi, and some viruses by disrupting their cell membranes. It also modulates the immune response, promotes wound healing, reduces inflammation, and has anti-biofilm activity against bacterial infections. | PNC27 contains two functional domains: residues 12-26 of the p53 HDM-2 binding domain on the N-terminus, and a membrane residency peptide (MRP/penetratin) on the C-terminus. Cancer cells uniquely express HDM-2 on their plasma membranes, while normal cells do not. PNC27 binds to this membrane-bound HDM-2, adopts an alpha-helical conformation similar to p53, and induces transmembrane pore formation. This causes extrusion of intracellular contents and rapid necrotic cell death. The peptide also enters cancer cells and disrupts mitochondrial membranes. Importantly, this mechanism is independent of intracellular p53 status - effective even in p53-null cancers. |
| Common Dosing | 100-200 mcg daily Once daily | No human dose - research compound only Not applicable - no human use |
| Administration | Subcutaneous injection or topical | IV injection in animal studies - not for human use |
| Typical Duration | Variable by protocol | Research protocols only - no human use data |
| Best Time to Take | Morning | Per research protocol |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Research demonstrates broad antimicrobial activity including against antibiotic-resistant bacteria. Studies show wound healing benefits, anti-biofilm effects, and immune modulation. Being investigated for chronic infections and wound healing applications. | Extensive in vitro research demonstrates PNC27 selectively kills multiple cancer cell types including breast (MCF-7), pancreatic (MIA-PaCa-2), cervical (HeLa, SW756), ovarian (OVCAR-3, OV-90), colon, lung, and leukemia (K562, U937, HL-60) cell lines. Effective concentration: 0.1-0.2 mg/mL kills most cancer cells. At 0.3 mg/mL, nearly 100% of K562 leukemia cells were killed. Studies confirm no toxicity to normal cells including fibroblasts and leukocytes. Mechanism involves membrane pore formation and necrosis (not apoptosis). Research published in PNAS and multiple peer-reviewed journals. |
Frequently Asked Questions: LL-37 vs PNC27
What is the difference between LL-37 and PNC27?
LL-37 is a immune peptide that a naturally occurring antimicrobial peptide and the only human cathelicidin. part of the innate immune system with broad-spectrum antimicrobial activity. PNC27 is a immune peptide that a chimeric anti-cancer peptide containing p53 residues 12-26 linked to a membrane-penetrating sequence. selectively kills cancer cells by binding to hdm-2 expressed on cancer cell membranes, inducing membrane pore formation and necrosis while leaving normal cells unaffected. The main differences lie in their mechanisms of action and clinical applications.
Which is better, LL-37 or PNC27?
Neither is universally "better" - the choice depends on your specific goals. LL-37 is typically used for immune purposes, while PNC27 is used for immune. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can LL-37 and PNC27 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using LL-37 and PNC27 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of LL-37 and PNC27 is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.